Therapeutic Use of the LNG IUS, and Counseling

review OA: closed CC0 ⤵ 7 in-corpus citations
AI-generated summary by gemini-2.5-flash-lite, 2026-06-11

This review discusses the therapeutic uses of the levonorgestrel-releasing intrauterine system for conditions like anemia, menorrhagia, dysmenorrhea, endometriosis, and tamoxifen-induced endometrial changes, emphasizing provider training and user counseling.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

The intrauterine release of levonorgestrel (LNG) alters the function of the endometrium. This phenomenon offers special health benefits for users and a manner of local intrauterine therapy. In this review we discuss use of LNG-releasing intrauterine system (LNG IUS) in treatment and prevention of anemia and in the therapy of menorrhagia and dysmenorrhea. The antiproliferative effect of the LNG IUS on the endometrium offers targeted therapy against the proliferative action of estrogen on the endometrium during hormone replacement therapy. The LNG IUS as an alternative to sterilization is also discussed. There are also promising therapeutic fields such as use of the LNG IUS in the treatment of endometriosis and in the protection of endometrium exposed to tamoxifen during breast cancer treatment. Special attention is paid to counseling because successful use of the LNG IUS requires good training of the providers and extensive counseling of users.
Full text 10,107 characters · extracted from oa-doi-fallback · 3 sections · click to expand

Abstract

The intrauterine release of levonorgestrel (LNG) alters the function of the endometrium. This phenomenon offers special health benefits for users and a manner of local intrauterine therapy. In this review we discuss use of LNG-releasing intrauterine system (LNG IUS) in treatment and prevention of anemia and in the therapy of menorrhagia and dysmenorrhea. The antiproliferative effect of the LNG IUS on the endometrium offers targeted therapy against the proliferative action of estrogen on the endometrium during hormone replacement therapy. The LNG IUS as an alternative to sterilization is also discussed. There are also promising therapeutic fields such as use of the LNG IUS in the treatment of endometriosis and in the protection of endometrium exposed to tamoxifen during breast cancer treatment. Special attention is paid to counseling because successful use of the LNG IUS requires good training of the providers and extensive counseling of users.

Keyword

Levonorgestrel - LNG IUS - menorrhagia - HRT - counseling

References

- 1 Luukkainen T, Lähteenmäki P, Toivonen J. Three years' experience with levonorgestrel-releasing intrauterine device and Norplant-2 implants: a randomized comparative study. Adv Contracept . 1992; 8 105-114 - 2 Sivin I, Alvarez F, Diaz J. Intrauterine contraception with copper and with levonorgestrel: a randomised study of the Tcu380Ag and levonorgestrel 20 μg/day devices. Contraception . 1984; 30 443-456 - 3 Nilsson C G, Luukkainen T, Arko H. Endometrial morphology of women using a d-norgestrel-releasing intrauterine device. Fertil Steril . 1978; 29 397-401 - 4 Silverberg S G, Haukkamaa M, Arko H, Nilsson C G, Luukkainen T. Endometrial morphology during long-term use of levonorgestrel-releasing intrauterine devices. Int J Gynecol Pathol . 1986; 3 235-241 - 5 Jones R L, Critchley H O. Morphological and functional changes in human endometrium following intrauterine levonorgestrel delivery. Hum Reprod . 2000 (suppl 3); 15 (162-172) - 6 Rutanen E-M. Insulin-like growth factors and insulin-like growth factor binding proteins in the endometrium: effect of intrauterine levonorgestrel delivery. Hum Reprod . 2000 (suppl 3); 15 (173-181) - 7 Nilsson C G, Lähteenmäki P L, Luukkainen T. Ovarian function in amenorrheic and menstruating users of a levonorgestrel-releasing intrauterine device. Fertil Steril . 1984; 41 52-55 - 8 Barbosa I, Bakos O, Olsson S E, Odlind V, Johansson E D. Ovarian function during use of a levonorgestrel-releasing IUD. Contraception . 1990; 42 51-66 - 9 Wood C. Menorrhagia: a management update. Modern Medicine of Australia . 1999; 42 65-75 - 10 Hallberg L, Högdahl A M, Nilsson L, Rybo G. Menstrual blood loss: a population study. Acta Obstet Gynecol Scand . 1966; 45 320-351 - 11 Cohen B J, Gibor Y. Anemia and menstrual blood loss. Obstet Gynecol Surv . 1980; 35 597-618 - 12 Luukkainen T, Allonen H, Haukkamaa M. Effective contraception with the levonorgestrel-releasing intrauterine device: 12-month report of a European multicenter study. Contraception . 1987; 36 169-179 - 13 Andersson K, Odlind V, Rybo G. Levonorgestrel-releasing and copper-releasing (Nova T) IUDs during five years of use: a randomized comparative trial. Contraception . 1994; 49 56-72 - 14 Faundes A, Alvarez F, Brache V, Tejada A S. The role of the levonorgestrel IUD in the prevention and treatment of iron deficiency anemia during fertility regulation. Int J Gynecol Obstet . 1988; 26 429-433 - 15 Andersson J K, Rybo G. Levonorgestrel-releasing intrauterine device in the treatment of menorrhagia. Br J Obstet Gynaecol . 1990; 97 690-694 - 16 Milsom I, Andersson K, Andersch B, Rybo G. A comparison of flurbiprofen, tranexamic acid and a levonorgestrel-releasing intrauterine contraceptive device in the treatment of idiopathic menorrhagia. Am J Obstet Gynecol . 1991; 164 879-883 - 17 Tang G W, Loa S S. Levonorgestrel intrauterine device in the treatment of menorrhagia in Chinese women: efficacy versus acceptability. Contraception . 1995; 51 231-235 - 18 Brechin S, Cameron S T, Paterson A M, Williams A R, Critchley H O. Intrauterine polyps-a cause of unscheduled bleeding in women using the levonorgestrel intrauterine system: case report. Hum Reprod . 2000; 15 650-652 - 19 Irvine G A, Campbell Brown B M, Lumsden M A, Heikkilä A, Walker J J, Cameron I T. Randomized comparative trial of the levonorgestrel intrauterine system and norethisterone for treatment of idiopathic menorrhagia. Br J Obstet Gynaecol . 1998; 105 592-820 - 20 Hallberg L, Nilsson I. Determination of menstrual blood loss. Scand J Lab Invest . 1964; 16 244-248 - 21 Crosignani P G, Vercellini P, Mosconi P, Oldani S, Cortesi I, De Giorgi O. Levonorgestrel-releasing intrauterine device versus hysteroscopic endometrial resection in the treatment of dysfunctional uterine bleeding. Obstet Gynecol . 1997; 90 257-263 - 22 Kittelsen N, Istre O A. A randomized study comparing levonorgestrel intrauterine system (LNG IUS) and transcervical resection of the endometrium (TRCE) in the treatment of menorrhagia: preliminary results. Gynaecol Endoscopy . 1998; 7 61-65 - 23 Romer T. Prospective comparison study of levonorgestrel IUD versus Roller-Ball endometrial ablation in the management of refractory recurrent hypermenorrhea. Eur J Obstet Gynecol Reprod Biol . 2000; 90 27-29 - 24 Lähteenmäki P, Haukkamaa M, Puolakka J. Open randomized study of use of levonorgestrel intrauterine system as alternative to hysterectomy. BMJ . 1998; 316 1122-1126 - 25 Lethaby A E, Cooke I, Rees M. Progesterone/progestogen-releasing intrauterine systems versus either placebo or any other medication for heavy menstrual bleeding. Cochrane Database Syst Rev . 2000; 2 CD002126 - 26 Stewart A, Cummins C, Gold L, Jordan R, Phillips W. The effectiveness of the levonorgestrel-releasing intrauterine system in menorrhagia: a systematic review. Br J Obstet Gynaecol . 2001; 108 74-86 - 27 Hurskainen R, Teperi J, Rissanen P. Quality of life and cost-effectiveness of levonorgestrel-releasing intrauterine system versus hysterectomy for treatment of menorrhagia: a randomized trial. Lancet . 2001; 357 273-277 - 28 Scholten P C. The Levonorgestrel IUD: Clinical Performance and Impact on Menstruation [dissertation]. Utrecht, The Netherlands: University Hospital of Utrecht; 1989 - 29 Barrington J W, Bowen-Simpkins P. The levonorgestrel intrauterine system in the management of menorrhagia. Br J Obstet Gynaecol . 1997; 104 614-616 - 30 Jones R L, Critchley H O. Morphological and functional changes in human endometrium following intrauterine levonorgestrel delivery. Hum Reprod . 2000 (suppl 3); 15 (162-172) - 31 Smith D C, Prentice R, Thomson D J, Herrmann W L. Association of exogenous estrogen and endometrial carcinoma. N Engl J Med . 1975; 293 1164-1167 - 32 Schairer C, Lubin J, Troisi R. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. JAMA . 2000; 283 485-491 - 33 Pike M C, Ross R K. Progestins and menopause: epidemiological studies of risks of endometrial and breast cancer. Steroids . 2000; 65 659-664 - 34 Nilsson C G, Haukkamaa M, Vierola H, Luukkainen T. Tissue concentrations of levonorgestrel in women using a levonorgestrel-releasing IUD. Contraception . 1982; 17 529-536 - 35 Andersson K, Mattsson L-O, Rybo G, Stanberg E. Intrauterine release of levonorgestrel: a new way of adding progestogen in hormone replacement therapy. Obstet Gynecol . 1992; 79 963-967 - 36 Raudaskoski T H, Lahti E I, Kauppila A J. Transdermal estrogen with a levonorgestrel-releasing intrauterine device for climacteric complaints: clinical and endometrial response. Am J Obstet Gynecol . 1995; 172 114-119 - 37 Sivin I, Stern J. Health during prolonged use of levonorgestrel 20 ug/d and the copper TCu 380Ag intrauterine contraceptive devices. Fertil Steril . 1994; 61 70-77 - 38 Faundes A, Alvarez F, Diaz J. A Latin American experience with levonorgestrel IUD. Ann Med . 1993; 25 149-153 - 39 Mishell Jr R D. Intrauterine devices: mechanism of action, safety, and efficacy. Contraception . 1998; 58 45S-53S - 40 Peterson H B, Xia Z, Hughes J M. The risk of ectopic pregnancy after tubal sterilization. N Engl J Med . 1997; 336 762-767 - 41 Sumiala S, Tuominen J, Irjala K, Klemi P, Mäenpää J. Luteal function declines after laparoscopic sterilization by Hulka or Filshie clips. Contraception . 2000; 62 177-180 - 42 MacDonald S R, Klock S C, Milad M P. Long-term outcome of nonconservative surgery (hysterectomy) for endometriosis-associated pain in women <30 years old. Am J Obstet Gynecol . 1999; 180 1360-1363 - 43 Vercellini P, Aimi G, Panazza S, De Giorgi O, Pesole A, Crosignani P G. A levonorgestrel-releasing intrauterine system for the treatment of dysmenorrhea associated with endometriosis: a pilot study. Fertil Steril . 1999; 72 505-508 - 44 Fedele L, Bianchi S, Zanconato G, Portuese A, Raffaelli R. Use of a levonorgestrel-releasing intrauterine device in the treatment of rectovaginal endometriosis. Fertil Steril . 2001; 75 485-488 - 45 Fedele L, Bianchi S, Raffaelli R, Portuese A, Dorta M. Treatment of adenomyosis-associated menorrhagia with a levonorgestrel-releasing intrauterine device. Fertil Steril . 1997; 68 426-429 - 46 Fong Y F, Singh K. Medical treatment of a grossly enlarged adenomyotic uterus with the levonorgestrel-releasing intrauterine system. Contraception . 1999; 60 173-175 - 47 Gardner F JE, Konje J C, Abrams K R. Endometrial protection from tamoxifen-stimulated changes by a levonorgestrel-releasing intrauterine system: a randomized controlled study. Lancet . 2000; 356 1711-1717 - 48 Mishell Jr D R. The clinic factor in evaluating IUDs. In: Hefnavi F, Segal SJ, eds. Analysis of Intrauterine Contraception Amsterdam: North Holland 1975: 27-36 - 49 Lei Z-W, Wu S C, Garceau R J. Effects of pretreatment counseling on discontinuation rates in Chinese women given depo-medroxyprogesterone acetate for contraception. Contraception . 1996; 53 357-361

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Condition tags

endometriosisdysmenorrhea

MeSH descriptors

Contraceptive Agents, Female Intrauterine Devices, Medicated Levonorgestrel Anemia Anemia Anemia Antineoplastic Combined Chemotherapy Protocols Antineoplastic Combined Chemotherapy Protocols Breast Neoplasms Breast Neoplasms Contraceptive Agents, Female Contraceptive Agents, Female Counseling Endometriosis Endometriosis Female Hormone Replacement Therapy Humans Levonorgestrel Levonorgestrel

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

Cited by (5)

Source provenance

europepmc
last seen: 2026-08-22T06:09:51.966504+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:13:13.417725+00:00
unpaywall
last seen: 2026-08-21T06:37:11.537704+00:00
License: CC0 · commercial use OK